Expression profiling by high throughput sequencing
Summary
We investigated the dynamics of gene expression in blood samples of IBD patients treated with infliximab and vedolizumab and analyzed the predictive potential regarding therapy outcome.
Overall design
We performed a longitudinal, blood-based multi-omics study in two prospective IBD patient cohorts receiving first time infliximab therapy (discovery: 14 patients, replication: 23 patients) and one prospective IBD patient cohort receiving first time vedolizumab therapy (17 patients). Samples were collected at up to 7 timepoints (from baseline to 14 weeks after therapy induction).